Posted by
Juanmonino/E+ via Getty Images
InflaRx (NASDAQ:IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients experiencing acute respiratory distress.
The European Commission granted marketing authorization under exceptional circumstances for Gohibic, also known as vilobelimab, for the treatment of adult patients